GFP/Luc Reporter Cell Line - U14

U14 is a murine cervical squamous carcinoma cell line that has been extensively used in tumor biology, immuno-oncology, and preclinical therapeutic studies. Originally established from a spontaneous cervical carcinoma in mice, U14 cells exhibit robust tumorigenicity and can readily form tumors in syngeneic mouse models, making them particularly valuable for evaluating anti-cancer therapies in immunocompetent hosts. The GFP/Luc Reporter Cell Line - U14 is generated through stable introduction of green fluorescent protein (GFP) and firefly luciferase (Luc) reporter genes into U14 cells. This dual-reporter system enables sensitive fluorescence detection and quantitative bioluminescence imaging while preserving the growth characteristics and tumor-forming capacity of the parental U14 cell line. The combined reporter expression facilitates real-time visualization and longitudinal monitoring of tumor cells in both in vitro and in vivo experimental settings.

The U14-GFP/Luc reporter cell line is widely used for establishing syngeneic mouse tumor models to investigate tumor progression, invasion, metastasis, and anti-tumor immune responses. Luciferase expression allows non-invasive bioluminescence imaging of tumor burden in living animals, enabling continuous assessment of disease progression and therapeutic efficacy without the need for repeated invasive procedures. GFP expression provides an additional tool for tracking cellular localization, morphology, and dissemination in cultured cells and tissue specimens. This model is particularly useful for evaluating chemotherapeutic agents, immunotherapies, gene therapies, and combination treatment strategies in immunocompetent mice. In addition, the U14-GFP/Luc cell line supports studies of tumor-host interactions, immune cell infiltration, and mechanisms underlying cervical cancer development and metastasis. Owing to its stable reporter expression and reliable tumorigenic properties, the U14-GFP/Luc model serves as a versatile and reproducible platform for preclinical oncology research and therapeutic development.